To report the use of recombinant activated factor VII (rFVIIa) in controlling life-threatening bleeding episodes in patients with grades III and IV Dengue Hemorrhagic Fever (DHF), also known as Dengue Shock Syndrome. Fifteen patients (seven boys, eight girls), whose median age was 8 years, were enrolled in the study. They were divided into two groups. Group 1 included nine patients, mainly grade III, waiting for platelet concentrate, and group 2 included six patients, mainly grade IV, who had already received platelet concentrate with unresponsiveness. A single dose or repeated doses of 100 ìg/kg rFVIIa was/were given at intervals of 4 h according to the bleeding symptoms. The median times from the onset of bleeding to rFVIIa initiation were 6.5 and 29.8 h in groups 1 and 2, respectively. Each patient received one to three doses. An effective response was found in eight patients (53.3%), including six patients in group 1 and two patients in group 2. They had complete cessation of bleeding without recurrence for 48 h. An ineffective response was found in seven patients (46.7%) including three patients in group 1 and four patients in group 2 for which the bleeding recurred (n 2), temporarily slowed down (n 3), continued (n 1) or occurred at a new site (n 1). These included three patients in profound shock 24-48 h before referral to comprehensive treatment centers, two patients receiving ibuprofen before hospitalization, one patient with extensive volume overloading, and one patient requiring surgical intervention to ligate the torn intercostal artery and vein. The platelet concentrate was promptly transfused to stop bleeding in patients with ineffective responses. The results revealed that the earlier initiation of rFVIIa in the mainly grade III DHF in group 1 yielded a higher effective response (66.7%) than the delayed initiation in the mainly grade IV DHF in group 2 (33.3%). Moreover, patients previously receiving ibuprofen or volume expander of low molecular weight dextran or urea-linked gelatin tended to have lower effective responses (28.6%) than patients without associated medication (75.0%). Ultimately, three of six patients with grade IV DHF died, while all nine patients with grade III DHF survived. Thus, the case-fatality rate in this study was 20%. No clinical evidence of thromboembolic complications was observed. rFVIIa seems to be effective in restoring hemostasis in a limited series of patients with Dengue Shock Syndrome exhibiting life-threatening bleeding episodes. Further study is warranted. 
Introduction
Dengue infection is the most common mosquito-borne viral disease of public health significance. It is caused by any of the four serotypes (dengue 1-dengue 4). The clinical manifestations range from asymptomatic infection, undifferential fever, an influenza-like symptom known as dengue fever to a severe, sometimes fatal disease characterized by hemorrhage and shock known as Dengue Hemorrhagic Fever (DHF) or Dengue Shock Syndrome (DSS). The first and second reported epidemics of DHF occurred in Manila in 1954 and 1956, followed by the third in Bangkok in 1958. Since then, DHF has spread throughout tropical Asian countries and has expanded globally [1] . DHF is manifested by high fever, bleeding diathesis, hepatomegaly and circulatory disturbance presented as shock in severe cases [2] . Bleeding diathesis is caused by vasculopathy, thrombocytopenia and mild coagulopathy, leading to petechiae, ecchymosis, epistaxis, hematemesis and melena [3] [4] [5] . There are three stages of DHF [2] , namely febrile, toxic and convalescent. The febrile stage lasts 2-7 days followed by an abrupt fall to normal or subnormal levels of temperature; the toxic stage lasts 24-48 h and, finally, rapid clinical recovery without sequalae in the convalescent stage. The toxic stage is the most critical period. Shortly after a rapid drop in temperature, varying degrees of circulatory distur-bance develop due to plasma leakage from increased vascular permeability. In mild degree [World Health Organization (WHO) grades I and II], the changes in vital signs are minimal and transient. In severe degree (WHO grades III and IV), also known as DSS, the blood pressure ranges from narrowing pulse pressure (, 20 mmHg) with a characteristically elevated diastolic pressure (e.g. 100/90 mmHg) to profound shock.
The most important aspect in managing patients with DHF is close observation by the clinician and constant nursing [6] . The optimal fluid therapy of isotonic salt solution is given to maintain the function of vital organs during the critical period. The extravascular fluid will spontaneously return to the intravascular compartment in the convalescent stage. If the hematocrit rises, fresh frozen plasma, 5% albumin or plasma expander should be administered as a rapid bolus. Over-treatment or under-treatment will lead to an unfavorable outcome. Blood grouping and matching should be carried out as a routine precaution for every patient with severe degree. In general, packed red blood cells (PRBC) and platelet concentrate are only indicated in patients with significant bleeding. PRBC is indicated for volume replacement in patients with severe bleeding. Platelet concentrate is indicated for controlling massive bleeding. Fresh frozen plasma and cryoprecipitate are indicated for patients where coagulopathy causes massive bleeding. Patients who do not receive appropriate treatment usually die within 12-24 h after the occurrence of shock. Prolonged shock is often complicated with metabolic acidosis that may precipitate disseminated intravascular coagulation (DIC) or enhance the ongoing DIC to aggravate massive bleeding [5] . The most common site is the gastrointestinal tract manifested by melena and/or hematemesis. Infrequently, the bleeding may be concealed leading to a more complicated course if unrecognized. Patients with massive bleeding may develop lethal shock, irreversible hepatic and renal failure leading to death. Therefore, prompt treatment of adequate fluid replacement and effective control of bleeding are essential for a favorable outcome.
Recently, recombinant activated factor VII (rFVIIa) was reported effective in controlling bleeding in patients with thrombocytopenia [7] or massive uncontrolled bleeding [8] . The present study reports the use of rFVIIa in patients with DSS in Thailand.
Methods

Patients
Fifteen DSS patients (seven boys, eight girls) with lifethreatening bleeding admitted to the comprehensive treatment centers located at four university hospitals and two regional hospitals from 2000 to 2002 in Thai-land were enrolled in the study, which was approved by the Faculty Ethics Committee. The informed consents were obtained from the parents. All of the patients were in the toxic stage of DSS. The median age was 8 years with an interquartile range of 5-13 years. They were divided into two groups as shown in Tables 1 and 2. Group 1 included nine patients (cases 1-9) who required platelet concentrate to stop bleeding. Four patients had already received 1 U PRBC and one patient had already received both PRBC and volume expander of urea-linked gelatin (Haemaccel), 10 ml/kg each. While waiting for platelet concentrate, the first dose of rFVIIa was administered. Group 2 included six patients (cases 10-15) whose bleeding manifestations were unresponsive to conventional blood component replacement of PRBC, fresh frozen plasma (FFP), cryoprecipitate and platelet concentrate, and low molecular weight dextran (dextran 40). In response, rFVIIa was given to stop bleeding. The rFVIIa (NovoSeven; Novo Nordisk A/S, Bagsvaerd, Denmark) of 100 ìg/kg was given as a single dose or repeated doses at intervals of 4 h according to the bleeding symptoms. After the administration of rFVIIa, the vital signs, clinical manifestations and content of bleeding were closely monitored and recorded.
The patients also received fully supportive treatment, airway management, fluid and electrolyte therapy, and appropriate antibiotics according to their clinical status and laboratory findings. Standard replacement therapy with blood components was used when necessary depending on the clinical manifestations assessed by the investigators. These indications included: PRBC for volume depletion from massive bleeding; FFP for volume replacement in cases of hemoconcentration with unstable blood pressure and a rapid pulse unresponsive to crystalloid fluid replacement or coagulopathy; and platelet concentrate from either single or random donors to stop active bleeding. One unit of single-donor apheresis platelet concentrate is equivalent to 8 U random-donor platelet concentrates.
In cases of epistaxis, anterior nasal packing with gelfoam was applied. A small nasogastric tube was gently inserted for draining the bloody content from the stomach in patients with hematemesis. Forceful nasogastric tube insertion and cold gastric lavage were contraindicated. In addition, a new sanitary pad was used for patients with hypermenorrhea before each injection of rFVIIa or each evaluation.
Diagnostic criteria
The clinical diagnosis [2] of DHF is based on four major characteristic manifestations: (1) high continuous fever lasting 2-7 days; (2) hemorrhagic tendency such as a positive tourniquet test, petechiae or purpura; (3) thrombocytopenia (platelet count < 100 000/ìl); and (4) evidence of plasma leakage due to increased vascular permeability manifested by hemoconcentration (an increase in hematocrit > 20%) or pleural effusion. The severity of DHF is categorized by four grades [2] : grade I, without overt bleeding but positive for the tourniquet test; grade II, with clinical bleeding diathesis such as epistaxis and ecchymosis; grade III, circulatory failure manifested by a rapid and weak pulse with narrowing pulse pressure; and grade IV, profound shock in which pulse and blood pressure are not detected. Grades III and IV are classified as DSS. In this study, the diagnosis of dengue infection was confirmed either by serological study with either a four-fold or more increase in the hemagglutination inhibition test between acute and convalescent sera, or by testing positive for dengue-specific IgM determined by enzyme-linked immunosorbent assay (ELISA).
Efficacy of bleeding control
The patients were closely monitored for evidence of bleeding at 15 min, 30 min, 45 min, 60 min, 2 h, 6 h, 12 h, 18 h, 24 h and 48 h after rFVIIa administration. The evidence of bleeding included any visualized bleeding, such as epistaxis, hematemesis, vaginal bleeding, hematuria, hematochezia. Also, internal bleeding, especially at the gastrointestinal tract, may be concealed and difficult to recognize in the presence of hemoconcentration. After the clinical evaluation of adequate volume replacement, internal bleeding was suspected in the following conditions [9] : (1) the patients with refractory shock, who had a hematocrit of less than 40% or a rapid drop in hematocrit (e.g. from 50 to 40%); (2) the systolic and diastolic blood pressure was elevated or normalized but the pulse was still rapid at . 130/min in children and . 150/min in infants younger than 1 year of age; and (3) a drop in hematocrit of more than 10% within 10 h of fluid replacement.
The treatment of rFVIIa was assessed as effective or ineffective by the investigators. An effective response signified that the bleeding completely stopped and did not recur within 48 h. Recurrence was defined as bleeding from the same site less than 48 h after successful treatment. An ineffective response signified that the bleeding had worsened, remained unchanged, temporarily slowed down, recurred or occurred at a new site. In patients with ineffective responses, the platelet concentrate was promptly transfused to stop bleeding.
Laboratory testing
The patient's blood was drawn by a two-syringe technique before and at 30 min after rFVIIa administration for determining the coagulation tests, factor VII clotting activity (FVII:C) and D-dimer. The FVII:C was assayed by manual tilt tube method of a one-stage technique based on the prothrombin time with human factor VII-deficient plasma from Diagnostica Stago (Asnieres-sur-Seine, France) as substrate [10] . FVII:C was expressed as IU/ml in relationship to normal plasma obtained from 10 healthy adults. The D-dimer was determined by a latex slide test (Murex D-dimer; Murex Biotech Ltd, Dartford, UK).
Statistical analysis
Chi-square or Fisher's exact test was used for discrete data, where appropriate. Mann-Whitney U or Wilcoxon Signed Ranks tests were used for continuous data. P , 0.05 was considered statistically significant.
Results
Thirty-three bleeding episodes including hematemesis (n ¼ 14), melena (n ¼ 7), hematochezia (n ¼ 2), hemothorax (n ¼ 4), hypermenorrhea (n ¼ 2) hematuria (n ¼ 2), epistaxis (n ¼ 1) and tooth extraction site bleeding (n ¼ 1) occurred among the 15 studied patients (Tables 1 and 2 ). They were classified as grades III and IV according to the WHO criteria. Patients in group 1 (cases 1-9) mainly included grade III DHF who exhibited cold and clammy skin, a rapid and weak pulse with or without narrowing pulse pressure. Patients in group 2 (cases 10-15) mainly included grade IV DHF who exhibited profound shock with undetectable pulse and blood pressure. The initial laboratory findings are presented in Table 3 . Six out of 15 (40%) patients had low hematocrit levels < 30%. Most of them (80%) had high levels of aspartate aminotransferase and alanine aminotransferase, suggesting liver impairment from dengue virus infection.
Replacement therapy and medication prior to rFVIIa administration
The patients received whole blood, PRBC, FFP, and cryoprecipitate as replacement for acute blood loss. Platelet concentrate was requested for all patients because of massive bleeding and thrombocytopenia. Patients in group 1 (cases 1-9) received rFVIIa while waiting for the platelet concentrate from the blood bank. Patients in group 2 (cases 10-15) had already received platelet concentrate in a dose of 0.2-0.9 U/kg with ineffective responses in controlling bleeding episodes. A total of four patients (cases 9, 10, 13 and 15) had also received low molecular weight dextran or urea-linked gelatin in the amount of 10-40 ml/kg before being referred to the comprehensive treatment centers.
Three patients (cases 1-3) received ibuprofen, a nonsteroid anti-inflammatory drug (NSAID), during the 3-5 days of febrile illness before hospitalization. The total amount was 14 tablets (200 mg/tablet) in case 1, 3 teaspoons (100 mg/5 ml) in case 2, and 5 teaspoons in case 3. Two patients (cases 1 and 4) received intravenous conjugated estrogen (Premarin) in a dose of 25 mg without responsiveness in case 1 and with responsiveness in case 4 at 2 h after the medication. Conjugated estrogen was continuously given at 6 h intervals for 24 h.
Efficacy of bleeding control
The treatment was considered effective in eight patients ( Tables 1 and 2 . These involved two patients (cases 1 and 3) receiving ibuprofen before hospitalization, one patient (case 9) with extensive volume overloading, three patients (cases 12-14) in profound shock, and one patient (case 10), who required surgical intervention to ligate the torn intercostal artery and vein.
Patients with effective responses did not require additional platelet concentrate transfusion. The median required PRBC before receiving rFVIIa among patients with effective responses was 8.0 ml/kg (interquartile range 0-31.7 ml/kg), which was lower than those after receiving rFVIIa (median 0, interquartile range 0-13.9 ml/kg). However, there was no significant difference. On the contrary, patients with ineffective responses required a prompt transfusion of additional platelet concentrate in a median dose of 0.4 U/kg to stop bleeding. They also required multiple transfusions of PRBC, FFP and cryoprecipitate to restore blood loss and hemostasis. The median required PRBC before receiving rFVIIa among patients with ineffective responses was 25.0 ml/kg (interquartile range 10.0-66.7 ml/kg), which was lower than those after receiving rFVIIa (median 15.6 ml/kg, interquartile range 14.3-50.0 ml/kg). However, there was no significant difference. Significantly, the required PRBC and platelet concentrate per kilogram among patients with effective responses were lower than those with ineffective responses, with P values of 0.025 and 0.0001, respectively.
At 30 min after the administration of rFVIIa, the median prothrombin times were significantly shortened from 18 s (interquartile range 14.9-24.9 s) to 12.2 s (interquartile range 9.5-14.5 s) (P ¼ 0.001). Also, the median level of FVII:C markedly increased from 0.74 IU/ml (interquartile range 0.4-1.0 IU/ml) to 20.0 IU/ml (interquartile range 13.7-34.0 IU/ml) (P ¼ 0.003). There was no statistically significant difference in the prothrombin times and levels of FVII:C between patients with effective and ineffective responses. Moreover, the levels of D-dimer of both groups were not significantly different from the pretreatment levels.
Utilized rFVIIa
The median times from the onset of bleeding to rFVIIa initiation were 6.5 and 29. 8 one patient (case 15) who received the second dose for attaining the hemostasis. Patients with ineffective responses received two to three doses. The dose intervals were at 4 h except for one patient (case 1) who received the second dose 10 min after the first dose. In total, the median dose of rFVIIa given was 100 and 250 ìg/kg in groups 1 and 2, respectively.
The initial laboratory findings of patients at admission
Factors affecting rFVIIa response
Possible factors affecting rFVIIa response, including age, gender, severity of disease, number of bleeding sites, duration of bleeding, medical treatment prior to rFVIIa administration, laboratory findings of hematocrits and platelet counts, were evaluated. Such factors had no significant association in response to rFVIIa. However, the earlier initiation of rFVIIa within 6 h in mainly grade III DHF in group 1 yielded a higher effective response (6/9 ¼ 66.7%) than the delayed initiation in mainly grade IV DHF in group 2 (2/6 ¼ 33.3%), but there was no significant difference. Also, patients previously receiving ibuprofen or volume expander of low molecular weight dextran or urea-linked gelatin tended to have lower effective responses (2/ 7 ¼ 28.6%) than patients without associated medication (6/8 ¼ 75.0%), but there was no significant difference.
Confirmation of dengue infection
Acute and convalescent sera were obtained from eight patients demonstrating a four-fold or more increase in the hemagglutination inhibition test. The convalescent titer was higher than 1 : 1280 in seven patients (cases 2, 3, 4, 5, 6, 10, and 15) defining secondary dengue infection and less than 1 : 1280 in one patient (case 9) defining primary dengue infection. Only a single specimen of late acute serum was obtained from the other seven patients, including three fatal cases. The results revealed positive dengue-specific IgM determined by ELISA.
Case-fatality rate
In total, the case-fatality rate was 20% (3/15). Three of six patients in grade IV DHF died while all nine patients in grade III DHF survived. The succumbed patients (cases 12, 13 and 14) were in profound shock 24-48 h before referral to the comprehensive treatment centers. The profound shock led to liver failure followed by renal failure. Although aggressive supportive treatment, including peritoneal dialysis, was provided, they died of multiple organ failure at 5 days, 40 h and 21 h after the administration of rFVIIa, respectively. No clinical evidence of thromboembolic complications was observed and no autopsy was performed.
Discussion
Successful treatment, which is mainly intensive supportive care, depends on early diagnosis of DHF and careful monitoring for shock. The management of DSS is a medical emergency requiring prompt and adequate fluid replacement for rapid and massive plasma leakage due to increased capillary permeability. Frequent monitoring of vital signs and hematocrits is essential in evaluating the treatment results. If hypovolemic shock is accompanied by massive bleeding, a grave prognosis will result. Risk factors of severe hemorrhage are the duration of shock and low-normal hematocrits at the time of shock [11] . Therefore, the prompt management of bleeding diathesis is essential since prolonged shock will lead to severe consumptive coagulopathy [5] followed by multiorgan failure.
The International Society on Thrombosis and Haemostasis DIC scoring system [12] was not used in the present study since the levels of fibrinogen were not determined and the levels of D-dimer were not completely available. However, using the available laboratory results, two patients (cases 5 and 14) had scores . 5 fulfilling the diagnostic criteria for overt DIC, and five patients (cases 2, 10, 11, 13 and 15) had scores of 4, suggestive of non-overt DIC, which tended to be overt DIC if the laboratory testing criteria were completely available. The findings were consistent with other studies revealing the occurrence of consumptive coagulopathy in patients with DHF even though they had no circulatory collapse [13] and overt DIC in patients with circulatory failure and prolonged shock [5] . The process of DIC might aggravate massive bleeding in patients with a severe degree of DHF.
Treatment with rFVIIa in the present study was limited by the prospective uncontrolled study design and the lack of autopsies among the fatal cases. The administration of rFVIIa seemed to be effective in six patients in group 1 with thrombocytopenia and in two patients in group 2 who were unresponsive to previous platelet concentrate transfusions. rFVIIa enhances thrombin generation and also enhances the activity and function of both the platelets of the patients and those transfused. The mechanisms appear to be by direct activation of factor X on the surface of activated platelets. The increased thrombin generation results in the formation of a firm fibrin clot [14] stabilized by factor XIII and activates thrombin-activatable fibrinolysis inhibitor, leading to a downregulation of fibrinolysis [15] .
Responses to rFVIIa administration tended to involve two factors: the delay between the onset of bleeding and the treatment, and the medication given prior to initiation of treatment. The study indicated that the earlier the rFVIIa initiation, the better the outcome. Patients with effective responses required a single dose 100 ìg/kg rFVIIa to stop bleeding while patients with ineffective responses required frequent administration of rFVIIa. Also, the infused volume expanders of low molecular weight dextran or urea-linked gelatin, or the ingested medication of NSAID, may aggravate bleeding in patients with thrombocytopenia. Both volume expanders decrease the factor VIII-von Willebrand complex [16] . The use of NSAID, like ibuprofen, aggravates bleeding in patients with thrombocytopenia. The ibuprofen-induced platelet dysfunction could not be overcome by the administration of rFVIIa. Although desmopressin is well known to be able to rapidly and almost fully reverse the adverse effects of NASID on platelet, it was not tried in the studied patients due to low platelet counts. The platelet dysfunction, induced by NSAID, might be dose-dependent. Since case 2 took ibuprofen in lesser amounts compared with cases 1 and 3, the patient's bleeding episodes were markedly reduced and only 1 U PRBC was transfused to correct the anemic state. Later, G6PD deficiency was diagnosed as the cause of hemolysis and hemoglobinuria in this patient.
The gastrointestinal tract was the most common site of severe bleeding episodes found in all patients in the present study, consistent with another report [17] . The manifestations varied from hematemesis and melena to hematochezia. The risk of bleeding was not solely based on the platelet count [11, 18] . The administration of excessive intravenous fluid to induce a rapid rise in blood pressure after circulatory collapse may aggravate bleeding by the sudden increased circulatory blood flow to the area of vascular damage such as gastric mucosa [19] . Moreover, antipyretic drugs such as NSAID and aspirin are other precipitating causes of gastritis. Therefore, appropriate fluid management and avoidance of NSAID or aspirin is warranted.
At present, dengue infection is more commonly found among older children, adolescents and adults [20] . In the present study, two adolescents (cases 1 and 4) exhibited hypermenorrhea. Since case 1 received a rather large amount of ibuprofen, the patient exhibited massive vaginal bleeding, which was unresponsive to both hormonal therapy and rFVIIa administration. Additional platelet concentrate transfusions were required to stop bleeding. Case 4 had hypermenorrhea requiring hormonal treatment. This patient's vaginal bleeding decreased after receiving hormonal treatment and almost completely ceased after receiving rFVIIa. Moreover, four patients (cases 10, 12, 13 and 14) exhibited hemothorax, which might be a complication of intercostal chest drainage procedures or ventilator support. Three patients (cases 12, 13 and 14) died while one patient (case 10) receiving the surgical intervention of ligating the torn intercostal artery and vein survived. Thus, in cases of continuous bleeding unresponsive to adequate replacement therapy combined with the administration of rFVIIa, surgical bleeding might be considered. Importantly, the hemostasis should be completely attained before the surgical intervention; otherwise, the patient will be vulnerable to more serious bleeding complications.
In the present study, patients with effective responses required smaller amounts of PRBC while patients with ineffective responses required multiple transfusions of platelet concentrate, PRBC, FFP and cryoprecipitate, increasing the risk of transfusion-transmitted diseases. As blood components, especially platelet concentrate, may not be immediately available in some hospitals, rFVIIa can be considered an alternative hemostatic agent in controlling bleeding episodes when appropriate. It is also attractive since it is produced by recombinant technology without exposure to human blood products.
In conclusion, the use of rFVIIa, given as bolus injection of 100 ìg/kg as a single dose or repeated doses at intervals of 4 h for one to three doses seems to be effective in restoring hemostasis to control life-threatening bleeding in a limited series of patients with DSS. Further studies to determine the optimal dosing of rFVIIa in a randomized and double-blind controlled design are warranted.
